Publication at Second Faculty of Medicine |
2019
Abstract
Emicizumab is a representant of so called non-factor replacement therapy for haemophilia A. It is a monoclonal bispecific antibody that mimics the function of FVIII as a cofactor in the FX activation complex, which is a necessary part of effective haemostasis.
Emicizumab has shown very good efficacy in clinical trials with patients with haemophilia A and inhibitors as well as with haemophiliacs A without inhibitors. It is not only an innovative treatment approach in terms of mechanism of action, but for hemophiliacs it is a revolutionary treatment in the sense of subcutaneous administration at intervals of once per week and even less frequently.